Episode 2: A View On: Antibody-Based Therapies

Antibody-Based Therapies: Transforming Modern Medicine

In this episode, we are joined by Ronnie Wei, Head of Biologics Discovery and Devel-opment at ModeX Therapeutics, and Atul Mohindra, Head of R&D for Biologics at Lon-za, to explore the development and manufacturing of monoclonal, bi-, and multi-specific antibodies and their transformative role in modern medicine.

Everyday life is filled with stories of medical breakthroughs—new cancer treatments, therapies for rare diseases, and vaccines that protect millions. At the heart of many of these advances are antibody-based therapies. These life-changing medicines leverage the natural defense systems of the body to target diseases with precision and effectiveness.

AI-Driven Innovation in Drug Development

Simon Wagschal, Associate Director of Small Molecules, highlights the transformative role of AI in drug development. His team’s AI-enabled route scouting process, recently recognized with a CPhI award, optimizes synthesis routes for complex molecules, shortening timelines and facilitating faster development. This approach is crucial for handling increasingly complex drug structures, which now average over 20 synthesis steps. Learn more here.

Discover how these therapies are made, the cutting-edge technologies behind them, and what the future holds for this rapidly evolving field. Whether you’ve benefited from an-tibody-based medicine yourself or are curious about the science behind these treatments, this episode will connect the dots between the lab and real life.

Curious to Learn More?

Join us in this conversation hosted by Dr. Martina Ribar Hestericová with ModeX Ther-apeutics’ Ronnie Wei and Lonza’s Atul Mohindra as they explore the transformative po-tential of monoclonal, bi-, and multi-specific antibodies in revolutionizing modern med-icine and biologics manufacturing.


Listen on:

moo moo logo
A View On podcast is produced by moomoostudios.com
KEY TERMS:

Bispecific Antibodies: Advanced antibody formats designed to target two antigens simultaneously. These mole-cules enhance therapeutic precision by addressing multiple disease pathways in a single treatment, reducing the need for combination therapies.

CHO Cells (Chinese Hamster Ovary Cells): The workhorse of biologics manufacturing, CHO cells are engineered to produce large quantities of therapeutic antibodies with human-like glycan profiles, ensuring safety and efficacy at scale.

Process Intensification: A manufacturing innovation aimed at increasing productivity in bioreactors. By optimiz-ing processes, such as transitioning from fed-batch to continuous methods, process in-tensification allows for higher yields in less time.

Antibody Engineering: The application of recombinant DNA and structural biology tools to design antibodies with enhanced specificity, affinity, and functionality, enabling therapies to better ad-dress complex diseases like cancer and autoimmune disorders.

Synergistic Binding: A unique feature of multi-specific antibodies where binding to multiple antigens ampli-fies therapeutic effects beyond what is achievable with individual monoclonal antibod-ies or antibody cocktails. This approach increases efficacy and reduces treatment com-plexity.

Past Episodes